Post procedural pregnancy occurrence risk after endometrial ablation.

Objective: The objective of the study was to analyse the pregnancy rate after curettage, 1G (Endometrial resection) and 2G (Endometrial ablation) procedures in women with abnormal uterine bleeding (AUB-O,E,N) to evaluate the rate of pregnancy following these procedures and to improve pre and post-therapeutic women information.
Methods: This retrospective study analyzed data extracted from the French Hospital medical information database. All hospital stays with a diagnostic code for AUB and an appropriate surgical procedure coded between 2009 and 2015 were identified. A total of 109,884 women were included. Of these, 88,165 were followed up for 18 months, 80,054 for 24 months and 33,251 for 60 months. Outcomes were compared between second generation (2G) procedures, first-generation (1G) procedures (endometrial resection) and curettage. The rate of pregnancy was the primary end point.
Results: 7863 women underwent a 2G surgical procedure (7.2%), 39,935 a 1G procedure (36.3%) and 38,923 a curettage (35.4%). The mean age of the women was 46 years (IC.95: 36.7-52.5), with no difference in age between groups. The rate of pregnancy after 2G, 1G and curettage was respectively 13 (1.5%), 617 (10.1%) and 1025 (11.1%). The primary endpoint was significantly different between 2G and 1G and curettage (p<0.0001) CONCLUSION: 2G procedures result in lower risk of pregnancy without requiring specific training for surgeons. However, endometrial ablation cannot be considered as a sterilization method nor an effective contraceptive procedure. In the absence of sterilization of either partner, women should continue to use contraception whatever their age and menstrual status.
Competing Interests: Conflict of interest DT has received personal fees from Hologic; PD has received personal fees from Hologic HF has received personal fees from Hologic, and discloses collaboration with Hologic, Bayer and Gedeon-Richter, Delmont. In addition to being investigators in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. PC declares non conflict of interest LL has received grants, via their company, from Hologic. The study was funded by Hologic, a company that markets NovaSure®, a radiofrequency endometrial ablation device. This does not alter our adherence to Plos One policies on sharing data and materials.
(Copyright © 2021. Published by Elsevier Masson SAS.)